P-034 Alnuctamab (ALNUC; BMS-986349; CC-93269), a BCMA × CD3 T-cell engager, in patients (pts) with relapsed/refractory multiple myeloma (RRMM): latest results from a phase 1 first-in-human clinical study
Clinical Lymphoma, Myeloma & Leukemia（2023）
关键词
relapsed/refractory multiple myeloma,multiple myeloma,alnuctamab,rrmm,t-cell,first-in-human
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要